| Trial ID: | L0111 |
| Source ID: | NCT02826525
|
| Associated Drug: |
AZD4076
|
| Title: |
AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease.
|
| Acronym: |
--
|
| Status: |
Completed
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
T2DM With NAFLD
|
| Interventions: |
Drug: AZD4076|Drug: Placebo
|
| Outcome Measures: |
The safety and tolerability of AZD4076 by assessing the number of participants with adverse events|The safety and tolerability of AZD4076 by assessment of blood pressure|The safety and tolerability of AZD4076 by assessment of pulse|The safety and tolerability of AZD4076 by assessment of oral temperature|The safety and tolerability of AZD4076 by assessment of electrocardiogram readings|The safety and tolerability of AZD4076 by assessment of digital electrocardiogram readings|The safety and tolerability AZD4076 by assessment of physical examination|The safety and tolerability of AZD4076 by assessing the injection site|The safety and tolerability of AZD4076 by assessing the number of adverse events|The safety and tolerability of AZD4076 by assessing hematology|The safety and tolerability of AZD4076 by assessing clinical chemistry|The safety and tolerability of AZD4076 by assessing urinalysis|Glucose infusion rate at hyperinsulinemic clamp|Reduction in liver fat content (%) per MRI|24 hour glucose area under the curve|HOMA-IR|Fasting Endogenous Glucose Production|AUCt of AZD4076 and longmer and shortmer metabolites|Matsuda Index|AUC0-24 of AZD4076 and longmer and shortmer metabolites|Cmax of AZD4076 and longmer and shortmer metabolites|Tmax of AZD4076 and longmer and shortmer metabolites|CLR of AZD4076 and longmer and shortmer metabolites|fe% of AZD4076 and longmer and shortmer metabolites|Ae of AZD4076 and longmer and shortmer metabolites
|
| Sponsor/Collaborators: |
AstraZeneca
|
| Gender: |
All
|
| Age: |
18 Years to 70 Years ?? (Adult, Older Adult)
|
| Phases: |
Phase 1
|
| Enrollment: |
14
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment
|
| Start Date: |
July 18, 2016
|
| Completion Date: |
October 11, 2019
|
| Results First Posted: |
--
|
| Last Update Posted: |
April 1, 2021
|
| Locations: |
--
|
| URL: |
https://ClinicalTrials.gov/show/NCT02826525
|
